2002

DOI: 10.1053/meta.2002.29024

|View full text |Cite

|

Sign up to set email alerts

|

Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: Effects on the very-low-density and high-density lipoprotein particle distribution

Francisco J. G rez

¹

,

Carlos A. Aguilar-Salinas

²

,

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

0

Mentioning

0

Contrasting

0

Year Published

2003

2003

2013

2013

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 12 publications

References 60 publications

Supporting

0

Mentioning

0

Contrasting

0

Order By: Relevance

Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes

¹

,

Mize²,

2013

Contemporary Diabetes

View full text Add to dashboard Cite

No abstract

Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes

¹

,

Mize²,

2013

Contemporary Diabetes

View full text Add to dashboard Cite

No abstract

Impact of thiazolidenediones on serum lipoprotein levels

¹

2006

Curr Atheroscler Rep

View full text Add to dashboard Cite

The thiazolidinediones, acting through peroxisome proliferator-activated receptor chi (PPARchi), affect multiple areas of metabolism. Of increasing importance is the recognition that these agents affect lipoprotein metabolism and cause changes in serum lipid and lipoprotein levels. All three thiazolidinediones, including troglitazone (which was withdrawn in the year 2000), rosiglitazone, and pioglitazone, tend to increase high-density lipoprotein (HDL) cholesterol, increase the size/decrease the density of low-density lipoprotein (LDL) particles, and raise the level of lipoprotein(a). In addition, troglitazone and pioglitazone, but not rosiglitazone, lower triglyceride levels modestly, thereby further contributing to increases in LDL and HDL size. The mechanism for these effects is still being clarified, but may involve enhancement of triglyceride clearance (in the case of pioglitazone), alteration of apolipoprotein C-III levels, reduction of hepatic lipase, and increase in ATP binding cassette A1 (ABCA1) activity. The clinical implications of these effects need further exploration.

Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

¹

,

²

,

³

et al. 2008

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

No abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2025 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.